## Fund objective

To outperform (after deduction of costs) the MSCI ACWI Index, as stated in sterling, by at least 2% per annum over rolling five-year periods.

The manager believes this is an appropriate target given the investment policy of the Fund and the approach taken by the manager when investing. In addition, the manager believes an appropriate performance comparison for this Fund is the Investment Association Global Sector.

There is no guarantee that this objective will be achieved over any time period and actual investment returns may differ from this objective, particularly over shorter time periods.

## Investment proposition

The Fund invests in an actively managed portfolio of stocks from around the world with the intention of delivering significantly higher total returns than the MSCI ACWI Index. We focus on companies which we believe offer above average profit growth and we invest with a long-term (5 year) perspective. The Fund's four dedicated investment managers draw on a combination of their own investment ideas and those of our various investment teams to produce a portfolio that typically holds 70-120 stocks.

## Periodic performance

| | 3 Months | 1 Year | 3 Years (p.a.) | 5 Years (p.a.) |
|---|---|---|---|---|
| Class B-Acc (%) | 9.2 | 15.4 | 12.9 | 6.4 |
| Index (%)* | 9.7 | 17.4 | 16.2 | 13.1 |
| Target (%)** | 10.2 | 19.8 | 18.6 | 15.4 |
| Sector Average (%)*** | 7.2 | 12.1 | 11.9 | 9.5 |
| Sector Ranking | 156/566 | 176/547 | 228/496 | 330/422 |

## Fund facts

| | |
|---|---|
| **Managers** | Malcolm MacColl* / Spencer Adair* / Helen Xiong* / Michael |
| **Fund launch date** | 08 March 2010 |
| **Fund Size** | £2,106.59m |
| **IA Sector** | Global |
| **Active share** | 78%† |
| **Annual turnover** | 21% |
| **Guideline number of holdings** | 70-120 |
| **Number of holdings** | 91 |
| **Structure** | OEIC |

*Partner.

†Relative to MSCI ACWI Index. Source: Baillie Gifford & Co, MSCI.

## Annual discrete performance

| | 30/09/20-30/09/21 | 30/09/21-30/09/22 | 30/09/22-30/09/23 | 30/09/23-30/09/24 | 30/09/24-30/09/25 |
|---|---|---|---|---|---|
| Class B-Acc (%) | 20.9 | -21.6 | 4.9 | 18.8 | 15.4 |
| Index (%)* | 22.7 | -3.7 | 11.0 | 20.4 | 17.4 |
| Target (%)** | 25.2 | -1.8 | 13.3 | 22.9 | 19.8 |
| Sector Average (%)*** | 23.2 | -8.9 | 7.8 | 16.2 | 12.1 |

Source: FE, Revolution, MSCI. Total return net of charges, in sterling.

Share class returns calculated using 10am prices, while the Index is calculated close-to-close.

*MSCI ACWI Index.

**MSCI ACWI Index (in sterling) plus at least 2% per annum over rolling five-year periods.

***IA Global Sector.

## Top ten holdings

| Holdings | % Total assets |
|---|---|
| NVIDIA | 5.8 |
| Meta Platforms | 4.5 |
| Microsoft | 4.4 |
| Prosus | 3.9 |
| TSMC | 3.8 |
| Amazon.com | 3.8 |
| DoorDash | 2.3 |
| Martin Marietta Materials | 2.2 |
| Mastercard | 2.1 |
| AppLovin | 2.1 |

## Stock level attribution

Top and bottom ten contributors to relative performance

Quarter to 30 September 2025

| Stock name | Contribution % |
|---|---|
| AppLovin | 0.9 |
| Prosus N.V. | 0.6 |
| CATL | 0.5 |
| CRH | 0.3 |
| FTAI Aviation | 0.3 |
| Medpace Holdings | 0.3 |
| Comfort Systems USA | 0.3 |
| Shopify | 0.2 |
| TSMC | 0.2 |
| Alnylam Pharmaceuticals | 0.2 |
| Apple | -0.6 |
| Elevance Health Inc | -0.5 |
| Tesla Inc | -0.3 |
| The Trade Desk | -0.3 |
| Adyen NV | -0.3 |
| Edenred | -0.2 |
| Alphabet | -0.2 |
| Meta Platforms Inc. | -0.2 |
| Novo Nordisk | -0.2 |
| Dutch Bros Inc. | -0.2 |

One year to 30 September 2025

| Stock name | Contribution % |
|---|---|
| Doordash Inc | 1.2 |
| Prosus N.V. | 1.1 |
| AppLovin | 0.9 |
| Shopify | 0.8 |
| Cloudflare Inc | 0.7 |
| SEA Ltd | 0.5 |
| NVIDIA | 0.5 |
| Comfort Systems USA | 0.4 |
| TSMC | 0.4 |
| Ryanair | 0.4 |
| Elevance Health Inc | -1.4 |
| Novo Nordisk | -0.9 |
| The Trade Desk | -0.8 |
| Broadcom Inc | -0.6 |
| Olympus | -0.5 |
| Tesla Inc | -0.4 |
| Builders Firstsource | -0.4 |
| Edenred | -0.4 |
| Palantir Technologies | -0.3 |
| BHP Group Ltd (Aus. listing) | -0.3 |

Source: Revolution, MSCI. Baillie Gifford Global Alpha Growth Fund relative to MSCI ACWI Index.
Some stocks may only have been held for part of the period.
All attribution figures are calculated gross of fees, relative to the Index from stock level up, based on closing prices.
As attribution is shown relative to the benchmark, not all stocks shown are held in the portfolio. See the List of Holdings section of this report for the stocks held.

## Sector

| | Fund (%) | Index (%) | Difference (%) |
|---|---|---|---|
| Information Technology | 25.4 | 27.2 | -1.7 |
| Consumer Discretionary | 21.2 | 10.7 | 10.6 |
| Financials | 13.3 | 17.4 | -4.1 |
| Industrials | 11.9 | 10.7 | 1.2 |
| Communication Services | 9.7 | 8.8 | 0.9 |
| Health Care | 7.8 | 8.5 | -0.7 |
| Materials | 5.0 | 3.6 | 1.4 |
| Consumer Staples | 1.9 | 5.3 | -3.4 |
| Real Estate | 1.8 | 1.9 | -0.1 |
| Energy | 1.4 | 3.5 | -2.1 |
| Cash | 0.7 | 0.0 | 0.7 |

## Geography

| Top ten locations | Fund (%) | Index (%) | Difference (%) |
|---|---|---|---|
| United States | 62.3 | 64.7 | -2.4 |
| Netherlands | 5.7 | 1.1 | 4.6 |
| Japan | 4.7 | 4.8 | -0.2 |
| Taiwan | 3.8 | 2.1 | 1.7 |
| China | 3.6 | 3.4 | 0.3 |
| Ireland | 3.2 | 0.1 | 3.1 |
| Canada | 3.1 | 2.9 | 0.2 |
| Brazil | 2.5 | 0.5 | 2.1 |
| South Korea | 1.9 | 1.2 | 0.7 |
| France | 1.6 | 2.4 | -0.8 |
| Total | 92.5 | 83.0 | - |

Source: Baillie Gifford & Co, MSCI. Index: MSCI ACWI Index. As well as cash in the bank, the cash balance includes unsettled cash flows arising from both shareholder flows and outstanding trades. Therefore, a negative balance may arise from timing differences between shareholder flows and security trading and does not necessarily represent a bank overdraft.

## Portfolio characteristics

| | Fund | Index |
|---|---|---|
| **Market Cap (weighted average)** | GBP 574.0bn | GBP 664.7bn |
| **Price/Book** | 5.3 | 3.5 |
| **Price/Earnings (12 months forward)** | 22.4 | 19.1 |
| **Earnings Growth (5 year historic)** | 14.4% | 11.7% |
| **Return on Equity** | 23.3% | 18.3% |
| **Predicted Beta (12 months)** | 1.3 | N/A |
| **Standard Deviation (trailing 3 years)** | 14.8 | 10.0 |
| **R-Squared** | 0.9 | N/A |
| **Delivered Tracking Error (12 months)** | 6.1 | N/A |
| **Sharpe Ratio** | 0.7 | 1.1 |
| **Information Ratio** | -0.2 | N/A |
| **Number of geographical locations** | 19 | N/A |
| **Number of sectors** | 10 | N/A |
| **Number of industries** | 41 | N/A |

Source: FactSet, Revolution, APT, Baillie Gifford & Co, MSCI. Index: MSCI ACWI Index. We have provided these characteristics for information purposes only. In particular, we do not think index relative metrics are suitable measures of risk. Fund and Index figures are calculated excluding negative earnings.

**Market environment**

Plus ça change, plus c'est la même chose. The more things change, the more they stay the same. After the short-lived market swoon following the drama of the 'Liberation Day' tariff announcements by President Trump back in April, the market environment over the most recent quarter has a distinctly familiar feel to it. Markets continue to rally, with the MSCI ACWI index reaching new all-time highs, led by artificial intelligence (AI) enthusiasm and the beneficiaries of the buildout of the associated datacentre infrastructure.

**Performance**

One company demonstrating the potential of new AI tools is AppLovin, the US-based advertising platform for mobile apps and one of the top contributors to performance over the quarter. AppLovin's proprietary AI-powered recommendation engine, AXON, is turbo-charging annual sales growth of over 70%, with profitability growing even faster. With its scale, advanced AI capabilities, and disciplined execution, AppLovin is increasingly positioned as a leading global performance advertising platform, and the market continues to reward that strength.

Medpace, a company which designs and conducts clinical trials on behalf of smaller biotechnology companies, was a new purchase during the quarter and another of the top contributors to performance. As the funding environment for biotechs has become more challenged over recent years, the number of active clinical trials being conducted has fallen, causing Medpace's growth to slow. Behind this lull, however, the pace of radical innovation in drug discovery has continued, creating a pent-up demand for Medpace's services. Hints that this recovery is starting to come through saw the share move sharply higher over the quarter. Our thesis is that this is likely just the start of a multi-year recovery.

Shopify, the ecommerce software giant, also contributed positively to performance as it reinforced its position as the operating system for modern retail. Results showing broad-based growth and particularly strong momentum in Europe, where Gross Merchandise Value (GMV) rose over 40 per cent last quarter. This acceleration highlights the portability of its model beyond North America and the strength of its global value proposition. Larger brands are increasingly adopting Shopify's modular components, while smaller merchants benefit from its integrated stack that lowers friction and boosts conversion. By unifying online and offline channels through point-of-sale, Shopify is building an ecosystem where scale, efficiency, and an expanding footprint reinforce one another, further cementing its leadership.

Detracting from performance, Elevance Health, the US health insurance provider, continues to face the challenge of rising medical costs, especially in its Medicaid and Affordable Care Act plans, which recently forced the company to cut its profit outlook. Membership losses from Medicaid redeterminations are adding to the pressure, while state reimbursement rates have been slow to adjust to higher expenses. With the stock trading at depressed levels due to these headwinds, we believe the market is overlooking the long-term value of Elevance's scale and critical integration in the US health system.

Another healthcare related business, Novo Nordisk, the maker of weight-loss drug Wegovy, was also among the largest detractors from relative returns. Novo cut its 2025 sales growth guidance from 17% to 11% due to copycat GLP-1 treatments and competitive pressure from Eli Lilly. While sentiment was also affected by a change in CEO, we see parallels with past downturns, such as 2016, when disciplined execution ultimately restored the company to growth. With the valuation now below 2016 levels, we believe prospects for a share price recovery are strong.

Edenred, the corporate benefits administrator, faced regulatory uncertainty in France and Brazil, with proposed reforms around digitalisation, voucher usage, and merchant fees weighing on sentiment. However, the feared cap on merchant fees now looks unlikely. Growth has also been unaffected as the company continues to benefit from structural drivers such as hybrid working and wellbeing initiatives. With digital penetration above 90% and sticky relationships with 60 million users and two million merchants, Edenred's scale advantages also remain intact.

**Notable transactions**

Over the quarter, the fund added four new names. These are MSCI, the leading provider of financial markets infrastructure including global equity indices and risk analytics, Medpace, mentioned earlier, The Ensign Group, the operator of skilled nursing and assisted living facilities and Coinbase, the leading US-based digital asset platform. These purchases were funded by the sales of Genmab, Atlas Copco, UnitedHealth, Soitec and Entegris.

**Market Outlook**

The outperformance of US markets, and their resulting dominance in global indices, has now been entrenched for so long - over fifteen years - that it's started to feel like a law of nature. However, much market commentary is focused on asking whether this divergence may be about to reverse. We would like to reframe the question. What matters to us is not the aggregate level of valuations in any individual market, but the qualities and characteristics of the companies available to us on a global basis, wherever they happen to be listed.

Transactions from 01 July 2025 to 30 September 2025.

**New Purchases**

| Stock name | Transaction rationale |
|---|---|
| Coinbase Global Inc | Coinbase is a trusted platform used by over 100 million people to safely move, store, and spend digital money. It is the largest provider of secure cryptocurrency storage for institutions, including most US Bitcoin ETFs. The market opportunity is vast, as crypto adoption continues to rise and regulatory tailwinds strengthen, particularly in the US. The company is expanding beyond trading into areas like payments, staking (earning rewards on crypto), and stablecoins (digital dollars that hold steady in value). The recent GENIUS Act in the US has given stablecoins (like Coinbase's own USDC) a clear regulatory framework, paving the way for mainstream adoption. Coinbase is already pushing USDC into real-world use cases such as payments with Shopify and low-cost cross-border transfers. It is also building Base, a faster, cheaper extension of one of the largest and most widely used blockchains, Ethereum, that could one day rival Visa and Mastercard as a payment network. At the same time, Coinbase is diversifying its revenue streams, steadily shifting toward more predictable recurring sources, including Coinbase One, a subscription service offering zero-fee trading, enhanced account protection, and priority support. We believe Coinbase's scale, market leadership, and product breadth provide a durable competitive advantage and leave the company well-positioned to capitalise on the evolving crypto economy. These attractions do not appear to be fully reflected in the company's current valuation, creating a compelling opportunity to take an initial position. |
| Medpace Holdings | Medpace designs and conducts clinical trials on behalf of smaller biotechnology companies. Its expertise in this area enables these customers to focus purely on research and development and helps accelerate the commercialisation of safe and effective drugs. Unlike competitors, Medpace only offers 'full-service' contracts, ensuring oversight of the entire process. This strategic focus, allied to a differentiated fixed-fee pricing structure, low-cost operations, and strong founder-led culture, has enabled Medpace to consistently gain market share while generating exceptional levels of free cash flow. As the funding environment for biotech companies has become more challenging over recent years, the number of active clinical trials being conducted has fallen, causing Medpace's growth to slow. However, the underlying pace of innovation in drug development remains strong, which we expect to underpin a recovery. With strong fundamentals and an attractive long-term growth opportunity, we have decided to take a holding. |
| MSCI | We have taken a new holding in MSCI, a leading provider of global investment tools and services. These include indices, portfolio risk and analytics, and ESG (environment, social, and governance) and climate data. MSCI is at the junction of several transformative trends in the investment landscape, which will support the company's future growth. Among these is the increasing diversification of investment strategies, which includes a growing interest in index-based funds. There is also growing demand for personalised benchmarks and ever more data and analytics to manage risk, attribute performance and report on new factors that are important to many clients, such as climate risks. The company's competitive advantage lies in its owner-operator CEO of 25 years, established index franchise, high client retention, and innovative analytics offerings. The current five-year low valuation presents an attractive entry point for a high-quality, structurally growing business with significant potential for long-term value creation. |
| The Ensign Group | The Ensign Group is a healthcare services company operating skilled nursing facilities, rehabilitative care services, home health, hospice, and assisted living services across the United States. Skilled nursing is fragmented and we think that Ensign will grow by steadily consolidating the sector, acquiring new operations and turning them around while continuing to drive operational improvements in existing homes. The company's strong, founder-initiated culture underpins its decentralised operating model, encouraging local leaders to grow and improve their clusters. The company's long-standing belief in nurturing leadership produces a steady stream of capable leaders to take on new acquisitions and transparency between facilities and clusters spreads best-practice. This effective culture both underwrites excellence at existing operations and facilitates the company taking on new ones. We think this could deliver mid-teens revenue growth for many years, with expanding margins via a combination of operating leverage and offering increasingly specialised services. With the quality and durability of these attractions far from recognised in the share price, we have decided to take a new holding for the Fund. |

### Complete Sales

| Stock name | Transaction rationale |
|---|---|
| Atlas Copco B | We have sold the holding in Swedish industrial equipment supplier, Atlas Copco. Atlas is a global engineering group which, in addition to its flagship industrial compressors business, possesses leading positions in pneumatic tools and construction. The company has delivered strong returns for the Fund since inception, driven by disciplined capital allocation, operational excellence and a decentralised, innovation-led culture. However, we believe these strengths are now fully priced in, with the company trading at 26 times' forward earnings. Considering the company's sensitivity to a higher interest rate environment, coupled with an evolving capital allocation strategy under the new CEO, our confidence in Atlas's ability to meet our return hurdle of doubling its share price over five years has diminished. We believe that our clients' capital could be better allocated to opportunities with clearer upside potential. |
| BHP Group Ltd - DI | We decided to sell the position in the diversified mining company BHP as the upside case was not strong enough to merit its place in the Fund. The company's iron assets are of very high quality and low cost, leading to improved returns as broader industry consolidation continues. However, the growth case was primarily based on demand for copper, a metal that, by its own admission, BHP has not sufficiently invested in. The fact that the management team's track record is patchy after failed shale oil and nickel investments and it is hard to build conviction in them exploiting any inflection in demand to deliver strong upside. While the company has delivered solid returns over our holding period due to growing dividends and brings different characteristics to the Fund, we believe it is time to move on. |
| Entegris Inc | Entegris is a supplier of consumables to the semiconductor industry. It provides specialty materials and chemicals as well as filtration, purification and handling products. Its edge is in the breadth and quality of its portfolio and the way its products are deeply integrated into its customers' processes. The company retains several attractions, but we have become less comfortable with the company's ability to navigate an environment that has become incrementally more challenging. Firstly, several areas of end demand for both logic and memory semiconductors remain cyclically depressed. Further, tariffs and the potential for export controls have resulted in an increasingly uncertain outlook, especially as sales to China have been rising as a proportion of overall demand. Finally, elevated debt levels have also both magnified earnings volatility and potentially limit Entegris' ability to continue to expand its product portfolio. With new holdings in several other semiconductor-related companies having been added earlier this year, the portfolio context has also evolved meaningfully. As a result, we have decided to sell the holding in Entegris. |
| Genmab | Genmab is a Danish biotech primarily focused on antibody drugs used to treat cancer. Over our holding period, the company has evolved from an immature research-focused biotech to one that takes a drug from discovery to market. It has delivered eight approved therapies and has over 20 in its pipeline. Despite this broadening, its blockbuster blood cancer drug Darzalex, first approved in 2015, continues to account for over 70% of total revenues. After losing a protracted legal battle with its partner Jannsen, and the company deciding not to license its next generation version, those revenues will disappear by 2031. It has three late-stage assets with blockbuster potential, but its ability to commercialise those drugs is unproven, as is the margins it can deliver through them. Despite its proven scientific expertise, the revenue gap to plug and execution risk were too high to maintain our holding. We decided to sell to reallocate the proceeds to higher conviction holdings. |
| Soitec | We have sold the holding in Soitec, the semiconductor materials company known for its engineered substrates. These layers help improve the performance and power efficiency of the silicon wafers used to manufacture semiconductor chips for smartphones, wireless and automotive applications. We purchased Soitec for the Fund in the expectation of a cyclical recovery in several of these end markets. However, this recovery has taken longer than anticipated as weakness has persisted in the automotive and smartphone end markets in particular. These trends have weighed on the share price, and the holding size has shrunk significantly. With new holdings in several other semiconductor-related companies having been added earlier this year, the portfolio context has evolved meaningfully from when we first purchased the shares in Soitec, and we have decided to move on from this small holding. |
| UnitedHealth | We have sold the holding in UnitedHealth Group (UHG), one of America's largest health insurance providers. Our original investment case was predicated on the growing need for healthcare coverage and potential for its value-based care proposition to improve patient outcomes, increase efficiency and drive profit growth. At the heart of the growth case was Optum, its vertically integrated solution that managed the main elements of healthcare provision from pharmacy and care delivery services to data analytics and solutions. However, the past year has been a challenging one for the healthcare sector as a whole. The overhang of regulatory uncertainty and rising healthcare costs has seen share prices fall across the board. UHG margins have come under pressure as medical loss ratios have increased, and its ability to price new business has come into question. The business withdrew its 2025 earnings guidance and replaced its CEO (reinstating a longstanding former incumbent). We are not inclined to add to the position, and by recycling this portfolio capital into a new position in Ensign, we have sought to broaden the Fund's healthcare exposure. |

## Voting activity

| Votes cast in favour | | Votes cast against | | Votes abstained/withheld | |
|---|---|---|---|---|---|
| Companies | 8 | Companies | 4 | Companies | None |
| Resolutions | 97 | Resolutions | 10 | Resolutions | None |

## Company engagement

| Engagement type | Company |
|---|---|
| Environmental | Alnylam Pharmaceuticals, Inc., Amazon.com, Inc., CBRE Group, Inc., Cloudflare, Inc., Contemporary Amperex Technology Co., Limited, Datadog, Inc., Markel Group Inc., Meta Platforms, Inc., Microsoft Corporation, Ryanair Holdings plc |
| Social | Amazon.com, Inc., Cloudflare, Inc., LVMH Moët Hennessy - Louis Vuitton, Societe Europeenne, Meta Platforms, Inc., Shopify Inc. |
| Governance | Alnylam Pharmaceuticals, Inc., Amazon.com, Inc., Arthur J. Gallagher & Co., AutoZone, Inc., CRH plc, Cloudflare, Inc., CoStar Group, Inc., Compagnie Financière Richemont SA, Floor & Decor Holdings, Inc., Markel Group Inc., Mastercard Incorporated, Meta Platforms, Inc., Netflix, Inc., ON Semiconductor Corporation, Petroleo Brasileiro S.A. - Petrobras, Prosus N.V., Royalty Pharma plc, Ryanair Holdings plc, Sartorius Stedim Biotech S.A., Shopify Inc., Spotify Technology S.A., Texas Instruments Incorporated, Thermo Fisher Scientific Inc. |
| Strategy | Amazon.com, Inc., Cloudflare, Inc., Contemporary Amperex Technology Co., Limited, Meta Platforms, Inc., Microsoft Corporation, Ryanair Holdings plc, Shopify Inc., Spotify Technology S.A. |

For further details on company engagement please contact us. You can also find further information on how we integrate environmental, social and governance (ESG) matters into our investment approach, here.

| Asset name | Fund % |
|---|---|
| NVIDIA | 5.8 |
| Meta Platforms | 4.5 |
| Microsoft | 4.4 |
| Prosus | 3.9 |
| TSMC | 3.8 |
| Amazon.com | 3.8 |
| DoorDash | 2.3 |
| Martin Marietta Materials | 2.2 |
| Mastercard | 2.1 |
| AppLovin | 2.1 |
| Service Corporation International | 2.0 |
| Alphabet | 1.9 |
| Shopify | 1.7 |
| Elevance Health Inc. | 1.7 |
| CRH | 1.7 |
| Ryanair | 1.5 |
| CATL | 1.5 |
| Royalty Pharma | 1.5 |
| AutoZone | 1.5 |
| AeroVironment | 1.4 |
| Sea Limited | 1.3 |
| Adyen | 1.3 |
| Block | 1.2 |
| AIA | 1.2 |
| CBRE Group Inc | 1.1 |
| Coupang | 1.1 |
| Uber Technologies | 1.1 |
| FTAI Aviation | 1.0 |
| Cloudflare | 1.0 |
| Netflix | 1.0 |
| MSCI | 0.9 |
| Richemont | 0.9 |
| Moody's | 0.9 |
| Markel | 0.9 |
| Paycom | 0.9 |
| Kokusai Electric Corporation | 0.9 |
| S&P Global Inc | 0.9 |
| Comfort Systems USA | 0.9 |
| Alnylam Pharmaceuticals | 0.9 |
| PDD Holdings | 0.9 |
| Texas Instruments | 0.8 |
| Reliance Industries | 0.8 |
| Samsung Electronics | 0.8 |
| Dollar General Corp | 0.8 |
| Novo Nordisk | 0.8 |
| B3 | 0.8 |
| Brookfield Corporation | 0.8 |
| Olympus | 0.8 |
| Medpace | 0.8 |
| Advanced Drainage Systems | 0.7 |
| Spotify | 0.7 |
| Disco | 0.7 |
| Li Auto | 0.7 |
| salesforce.com | 0.7 |
| On Semiconductor Corp | 0.6 |
| Eaton | 0.6 |
| The Ensign Group, Inc. | 0.6 |
| CoStar | 0.6 |
| AJ Gallagher | 0.6 |
| Datadog | 0.6 |
| Walt Disney | 0.6 |
| Nu Holdings | 0.6 |
| Stella-Jones | 0.6 |
| MercadoLibre | 0.6 |
| Edenred | 0.6 |
| The Trade Desk | 0.6 |
| EPAM Systems | 0.6 |
| Epiroc | 0.5 |
| Kweichow Moutai | 0.5 |
| Coinbase | 0.5 |
| Thermo Fisher Scientific | 0.5 |
| Petrobras | 0.5 |
| ASM International | 0.5 |
| Cosmos Pharmaceutical | 0.5 |
| Nexans | 0.5 |
| Nippon Paint | 0.5 |
| Rakuten | 0.5 |
| Dutch Bros | 0.5 |
| CyberAgent | 0.5 |
| Builders FirstSource | 0.4 |
| SMC | 0.4 |
| Bellway | 0.3 |
| Floor & Decor | 0.3 |

| | |
|---|---|
| LVMH | 0.3 |
| Brunswick Corp | 0.3 |
| WillScot Holdings | 0.3 |
| Enphase Energy | 0.2 |
| Sartorius Stedim Biotech | 0.2 |
| Mobileye | 0.1 |
| Sberbank | 0.0 |
| Abiomed CVR Line* | 0.0 |
| Cash | 0.7 |
| Total | 100.0 |

Please note the fund information contained within this document is proprietary information and should be maintained as such and not disseminated. The content is intended for information purposes only and should not be disclosed to other third parties or used for the purposes of market timing or seeking to gain an unfair advantage.

*Abiomed was acquired in December 2022 by Johnson and Johnson. Holders received a cash allocation plus non-tradable contingent value rights (CVRs).

| Share class | Share class inception date | ISIN | SEDOL | Annual management fee (%) | Ongoing charge figure (%) |
|---|---|---|---|---|---|
| Class B-Acc | 08 March 2010 | GB00B61DJ021 | B61DJ02 | 0.57 | 0.59 |
| Class B-Inc | 16 March 2010 | GB00B3PPZ729 | B3PPZ72 | 0.57 | 0.59 |

The table displays the primary shares classes. Other share classes may be available for those investors who have a separate arrangement. Charges will reduce the value of your investment. Please refer to the Prospectus and Key Investor Information Document for further details.

The Ongoing Charges Figure ('OCF') may be lower than previous declarations as a result of a revision to how the indirect fees associated with closed-ended investment companies need to be shown. This does not necessarily mean that fund expenses have gone down rather that we have reverted to how they have been calculated until 30 June 2022 to reflect the revised Investment Association's Guidance on Disclosure of Fund Charges and Costs (July 2020, updated January 2022, revised November 2023). A more detailed Costs and Charges disclosure is available upon request.

**MSCI**

This document contains information on investments which does not constitute independent investment research. Accordingly, it is not subject to the protections afforded to independent research and Baillie Gifford and its staff may have dealt in the investments concerned. Investment markets and conditions can change rapidly and as such the views expressed should not be taken as statements of fact nor should reliance be placed on these views when making investment decisions.

This document is issued by Baillie Gifford & Co Limited, Calton Square, 1 Greenside Row, Edinburgh EH1 3AN, a company which is authorised and regulated by the Financial Conduct Authority, Financial Services Register No. 119179, and is a member of The Investment Association. Baillie Gifford & Co Limited is wholly owned by Baillie Gifford & Co, which is authorised and regulated by the Financial Conduct Authority. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK clients. Both are authorised and regulated by the Financial Conduct Authority.

**Additional geographical location information**
**Israel**: This Report, as well as investment in the Fund described herein, is directed at and intended for Investors that fall within at least one category in each of: (1) the First Schedule of the Israeli Securities Law, 1968 (“Sophisticated Investors”); and (2) the First Schedule of the Investment Advice Law (“Qualified Clients”).

The Fund’s share price can be volatile due to movements in the prices of the underlying holdings and the basis on which the Fund is priced.

As with any investment, the clients’ capital is at risk. Past performance is not a guide to future returns.

Throughout the report all figures are rounded, so any totals may not sum. Not all stocks mentioned may be held by the portfolio.

All information as at 30 September 2025 and source is Baillie Gifford & Co unless otherwise stated.

**Baillie Gifford & Co Limited**
**Calton Square, 1 Greenside Row, Edinburgh EH1 3AN**
**Telephone +44 (0)131 275 2000 bailliegifford.com**



Ref: 177111